{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000014","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.196857+00:00","generated_at":"2026-06-20T05:19:42.075998+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023","bullets":["Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.","She brings expertise in immuno-oncology for CAR-M and checkpoint inhibitor combination trials.","Merger with Sesen Bio expected to close in Q1 2023, subject to stockholder approval and conditions.","Phase 1 trial of CT-0508 + Keytruda actively recruiting; first patient anticipated by end of Q1 2023.","Merger agreement amended Dec 29, 2022 to deliver greater value to Sesen Bio stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000014","json":"https://secwatch.observer/filing/0001485003-23-000014.json","markdown":"https://secwatch.observer/filing/0001485003-23-000014.md","text":"https://secwatch.observer/filing/0001485003-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/0001485003-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/sesn-20230131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:19:42.075998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}